Recent Updates
Recently added Catalysts

Multiple System Atrophy: two biotech companies racing to a treatment

Neurology & PsychiatryConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$4.9Buniverse median $1.20B
Allocated capital$1.1B$9.8B competing
Phase 3 or filed01 mid, 1 early
Pure plays0this indication only
Capital rank142/299crowding rank 91

Multiple System Atrophy is a two-horse race: Tiziana Life Sciences (TLSA, $117M) against Ionis Pharmaceuticals (IONS, $9.7B).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $1.1B of allocated capital sits on the pair.

IONS alone accounts for 99% of the $9.8B of market capitalisation competing here, so this is a leader plus a tail rather than a level race.

$1.1B of allocated capital sits in Multiple System Atrophy, ranking it 142nd of 299 indications by the money committed to it.

Companies developing drugs for Multiple System Atrophy 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
TLSATiziana Life SciencesForalumabPhase 21$117MNo3 31 Oct 2026
IONSIonis PharmaceuticalsION464Phase 11$9.7BNo9 22 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. IONS holds 99% of the $9.8B competing in this indication.

Why Multiple System Atrophy is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Multiple System Atrophy has 2 competitors and a median of $4.9B.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Pelizaeus Merzbacher Like Disease1 company · $1.1B · median $9.7BUncontestedNeurogenic Orthostatic Hypotension1 company · $887M · median $887MUncontestedTonic-Clonic Seizures1 company · $1.5B · median $5.8BUncontestedFrontotemporal Dementia1 company · $729M · median $3.6BUncontestedEpilepsy1 company · $639M · median $2.6BUncontestedDementia With Lewy Bodies1 company · $1.6B · median $4.8BUncontestedGeneralized Anxiety Disorder1 company · $1.7B · median $5.1BUncontestedAcute Ischemic Stroke2 companies · $486M · median $1.3BConcentrated bet

Multiple System Atrophy pipeline questions

Which biotech companies are developing drugs for Multiple System Atrophy?

Tiziana Life Sciences (TLSA, Foralumab, Phase 2); Ionis Pharmaceuticals (IONS, ION464, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Multiple System Atrophy.

How advanced is the Multiple System Atrophy pipeline?

Of the 2 clinical-stage programmes in Multiple System Atrophy, 0 are in Phase 3 or filed, 1 is in mid-stage development and 1 is in early-stage development.

Which company leads the Multiple System Atrophy field?

IONS is the largest developer in Multiple System Atrophy, holding 99% of the $9.8B of market capitalisation competing in the indication. The median competitor is worth $4.9B.

When is the next Multiple System Atrophy catalyst?

The next dated catalyst in Multiple System Atrophy is IONS on 22 Sep 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map